Assessing the risk of cardiovascular disease in patients with type 2 diabetes

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Articles by Mead, M.
	Search for Related Content

Social Bookmarking

	What's this?

Mike Mead

The Surgery, 2A Park Drive, Leicester Forest East, Leicester, LE3 3FN, UK, mikemead{at}talk21.com

References

The Audit commission. Testing Times. A Review of Diabetes Services in England and Wales 2001.

National Service Framework for Diabetes: Standards. Department of Health, December 2001.

Mills JD, Grant PJ Insulin resistance, haemostatic factors and cardiovascular risk. Br J Diabetes Vasc Dis 2002;2:19-26.[Abstract/Free Full Text]

Parott S., Godfrey C., Raw M., West R., Mcneill A. Smoking Cessation Guidelines and their Cost-effectiveness. Thorax 1998;53(suppl 5, part 1) S11.

Ukpds Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Ukpds Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Ukpds Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]

Ramsay Le, Williams B., Johnston GD et al. for the British Hypertension Society. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Parvin HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in-patients with type 2 diabetes. N Engl J Med 2000;345:870-8.[Web of Science]

MRC/ BHF Heart Protection Study. Findings presented at the American Heart Association's Scientific sessions, November 2001.

Rubins HB, Robins SJ, Collins D. et al. for the Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999:341;410-8.[Abstract/Free Full Text]

National Institute for Clinical Excellence. Guidance on the Use of Pioglitazone for type 2 Diabetes Mellitus. Technology Appraisal Guidance No 21, March 2001.

National Institute for Clinical Excellence. Guidance on Rosiglitazone for Type 2 Diabetes Mellitus. Technology Appraisal No 9, August 2000.

National Institute for Clinical Excellence. Inherited Clinical Guideline F. Management of type 2 diabetes: renal disease-prevention and early management, February 2002.

Scottish Intercollegiate Guidelines Network. 55. Management of diabetes. A national clinical guideline, November 2001.

National Institute for Clinical Excellence. Inherited Clinical Guideline E. Management of type 2 diabetes: retinopathy - screening and early management, February 2002.